Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Soledad Iseas, Jessica Serrand, S. Garcia Molina, V. Mammar et al.
Citations
4 citations
Journal
The Lancet Oncology
Topics
Colorectal and Anal Carcinomas
Field-Weighted Citation Impact (FWCI)
8.03
article
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Soledad Iseas, Jessica Serrand, S. Garcia Molina, V. Mammar, L. Quéro, Sarah Chennoufi, Jihane Boustani, David Tougeron, Stéfano Kim, François Ghiringhelli, Ludovic Evesque, Paolo Torielli, Lucile Montagné, Chloé Vernet, Clélia Coutzac, Angélique Vienot, Magali Rebucci-Peixoto, Olivier Bouché, H. Lamallem, F. Boulbair, Thierry Nguyen, Christophe Borg, Christophe Maritaz, Cédric Chevalier, Aurélia Meurisse, Benoist Chibaudel, Déwi Vernerey
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet OncologyVol. 26(12)
Institutions
Délégation Paris 5 (FR), Inserm (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre Georges François Leclerc (FR), Methodology and Quality of Life Unit in Oncology (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre Léon Bérard (FR), Centre Hospitalier Universitaire de Reims (FR), Centre Hospitalier Universitaire de Poitiers (FR), Hôpital Privé Jean Mermo (FR), Institut Hospitalier Franco Britannique (FR), Boehringer Ingelheim (France) (FR), Boehringer Ingelheim (China) (CN), Centre Antoine Lacassagne (FR), Université Marie et Louis Pasteur (FR), Université de Reims Champagne-Ardenne (FR)